Search Results 31-40 of 17057 for hla genotype

1. Clinical trials - Oncology (Medical)

   The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

2. A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression - Mayo Clinic

   A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression.

3. Heart Transplant Research Program - Transplant Research Center - Mayo Clinic Research

   Anti-human leukocyte antigen (anti-HLA) antibodies. Mayo Clinic heart researchers are exploring how to improve outcomes and reduce the risk of rejection in ...

4. The Role of Genetics and Socioeconomic Factors in Outcomes After Kidney Transplantation in Hispanics and American Indians - Mayo Clinic

   ... HLA typing and whole genome sequencing studies) to identify genes associated with transplant outcomes (diabetes, rejection and graft loss) in Hispanics and ...

5. Publications - Francisco Alvarez, M.D. - Mayo Clinic

   Clinical utility of 1:16 serum dilution as a predictor of response to therapeutic plasma exchange for HLA antibody-mediated rejection treatment and overall ...

6. VTP-1000 in celiac disease - Clinical Trials

   Presence of Human Leukocyte Antigen (HLA)-DQ2.5 genotype; Participants who are on a well controlled gluten restricted diet; Negative or weak positive anti ...

7. A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease - Mayo Clinic

   - HLA-DQ8 genotype. - Previous oral gluten challenge within 12 months. - Selective IgA deficiency. - Diagnosis of Type-1 diabetes. - Active gastrointestinal ...

8. A Study to Assess the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Celiac Disease Patients - Mayo Clinic

   Has HLA-DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygotes or heterozygotes). Has followed a GFD for > 12 months immediately prior to study entry ...

9. Stevens-Johnson syndrome - Symptoms & causes - Mayo Clinic

   HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clinical Pharmacology and Therapeutics. 2012;92:757. Wetter DA ...

10. Stevens-Johnson syndrome - Diagnosis & treatment - Mayo Clinic

    HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clinical Pharmacology and Therapeutics. 2012;92:757. Wetter DA ...